GS 1101: Phase III started

Gilead began the double-blind, placebo-controlled, international Phase III Study 116 trial to evaluate oral 150 mg GS-1101 twice daily in combination with rituximab in 160 previously treated CLL patients with measurable lymphadenopathy who have progressed less than 24 months after completing prior therapy and who are ineligible for cytotoxic therapy due to co-morbidities. Patients who tolerate initial therapy in the trial will be eligible for the double-blind Study 117 extension trial. Gilead has rights to GS-1101 through its 2011 acquisition of Calistoga Pharmaceuticals Inc. (see BioCentury, Feb. 28, 2011 & April 25, 2011). ...